about
Neuroimaging studies of striatum in cognition part II: Parkinson's diseaseReward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson’s diseaseα-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter.Monoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesManganese Neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmissionParkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisManganese-induced atypical parkinsonism is associated with altered Basal Ganglia activity and changes in tissue levels of monoamines in the ratThe relationships between mild cognitive impairment and phenotype in Parkinson's diseaseEffects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.Dynamic connectivity at rest predicts attention task performance.Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyondImplication of coronin 7 in body weight regulation in humans, mice and fliesA role for locus coeruleus in Parkinson tremor.Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptomsDeep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's diseaseTrait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?Noradrenergic modulation of cognition: therapeutic implications.Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts.In vitro Metabolomic Approaches to Investigating the Potential Biological Effects of Phenolic Compounds: An Update.Locus coeruleus.Resting-State Functional Connectivity of the Locus Coeruleus in Humans: In Comparison with the Ventral Tegmental Area/Substantia Nigra Pars Compacta and the Effects of Age.Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical ImplicationsExendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediatorsRemoving the blinkers: moving beyond striatal dopamine in Parkinson's disease.DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis.The cerebral basis of Parkinsonian tremor: A network perspective.11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.Quantitative Analysis of Catecholamines in the Pink1 -/- Rat Model of Early-onset Parkinson's Disease.Lead-Induced Atypical Parkinsonism in Rats: Behavioral, Electrophysiological, and Neurochemical Evidence for a Role of Noradrenaline Depletion.Effect of a single intrastriatal rotenone injection on oxidative stress and neurodegeneration in the rat brain
P2860
Q26779306-7D1D5A5A-A1C9-49D3-91F6-8134D8D66B5DQ27303483-80D97F88-A609-4A63-8797-056FAA5B1277Q27313863-E50F022C-2042-484F-BF3C-00BCD6735EB5Q28066691-39E3F3FF-D410-457C-8843-78F12BC88C0AQ28085179-C34C7766-9F17-4729-81EF-D7FFE3A61BBFQ28384572-5124AB8B-3E41-44CF-9389-81EBE71EE964Q28539360-67A48310-BE5A-4343-8A8B-B067DCD5F3FBQ33917203-0EA49D72-7738-4429-84C0-339FBAF9186DQ33918393-6A320943-A87F-434E-AC76-9A762B0816B0Q35036521-91D4850D-AAFF-41D1-802D-0082C443ACA0Q35120721-8BA2137F-CF4C-4069-A62A-7BF5EC2F1BE1Q35191447-B65F838A-8322-4FAF-8952-4EAB800C38DAQ35647270-673F4535-69A2-4B8A-AA77-CBD36B211610Q35942601-5B3ABFAD-781F-4F40-932D-820897D42854Q36568655-EDC43984-8801-4996-9283-FD5D0FF536A9Q36946063-57C29A84-651A-4F56-97FF-8DB8CAE27C55Q38091914-BB9E437C-8813-4C43-B994-F24592423772Q39249440-77440FFC-590E-47EC-910F-17BCF5E323D3Q39333401-C0F6C4C2-FF4E-4FCA-90B4-4985CC7C89F3Q39422119-FDAE7325-8386-40FC-A0CE-427D515B7FE3Q40681378-9D3F4A01-BBBD-4774-B5E5-EB3E7F690638Q41684008-CEFAE4FC-3558-440B-B219-A54DAA7CB0ABQ42388707-6477C1B6-39A3-476A-855A-E700BCC0A098Q42441161-722355AB-1259-426E-B7E8-19D001A61E7FQ46195232-DB715352-79AB-4C88-8867-D0FB485C2FEAQ47183061-596AF9BB-CB04-4FAC-BBE8-60EF72554AECQ47849922-22C221E8-B778-46D7-9A62-77D94708E117Q47995478-3047DD3A-FBF2-4333-BC9C-AF8749F8BB8CQ52370317-79E5D34A-005A-4D78-B018-5C4649BDE938Q53418820-4079258E-0978-43FB-B95B-4C558BF9ABA5Q57729898-EB9A78D0-B995-484D-9099-7642D82A4942
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Noradrenaline and Parkinson's disease.
@ast
Noradrenaline and Parkinson's disease.
@en
type
label
Noradrenaline and Parkinson's disease.
@ast
Noradrenaline and Parkinson's disease.
@en
prefLabel
Noradrenaline and Parkinson's disease.
@ast
Noradrenaline and Parkinson's disease.
@en
P2093
P2860
P356
P1476
Noradrenaline and Parkinson's disease.
@en
P2093
Abdelhamid Benazzouz
Claire Delaville
Philippe De Deurwaerdère
P2860
P356
10.3389/FNSYS.2011.00031
P577
2011-05-18T00:00:00Z